Ilant Health CEO Discusses Market Strategy with CB Insights

Ilant Health CEO Elina Onitskansky has provided insights into the company's market position and strategy during an interview with CB Insights.

Onitskansky described Ilant Health's operational space as the obesity and cardiometabolic health treatment market. The obesity treatment sector alone is valued at nearly $20 billion and is projected to reach $60 billion by 2030. When the broader cardiometabolic treatment market is included, the total market value likely exceeds $100 billion.

The company targets the business-to-business-to-consumer (B2B2C) segment, where employers and health plan buyers make benefit decisions. These decisions aim for clinically and financially beneficial outcomes, particularly in managing rising drug costs like GLP-1s and overall chronic disease expenses.

Ilant Health aims to enable employers and health plans to offer obesity and cardiometabolic treatments that yield significant chronic disease outcomes and long-term savings without incurring substantial short-term costs. The company highlights that obesity affects over 40% of U.S. adults and contributes to over $1 trillion in excess medical costs annually due to associated conditions.